Senhwa Biosciences Inc (生華科) yesterday said it has partnered with the US National Institutes of Health (NIH) to evaluate the efficacy of a new drug, dubbed Silmitasertib, for treatment of COVID-19.
The drug, developed by Senhwa Biosciences to treat cancers, such as bile duct cancer, medulloblastoma and pediatric brain tumor, showed promise in human tests to curb the ribonucleic acid (RNA) virus from proliferating.
“With the attribute, the drug is expected to help combat the novel coronavirus. We have not tested the drug on patients with COVID-19 in Taiwan, but the US NIH, looking forward to the drug’s efficacy, will run some trials in the US,” Senhwa Biosciences CEO Soong Tai-sen (宋台生) said by telephone.
The company would offer the drug for free to the US agency during the tests, but it is difficult to forecast when the trials would be completed, Soong said.
The New Taipei City-based firm has no intention of running human trials for COVID-19 treatment in Taiwan, as it has put all of its resources into its clinical trials on cancer treatment, but it is willing to partner with other companies and provide its drugs for free, Soong said.
The University of California San Francisco’s Quantitative Biosciences Institute last month identified 69 drugs or experimental compounds that might be effective in treating COVID-19, including the Silmitasertib, Soong said.
Silmitasertib could promote the formation of street granules by disrupting casein kinase 2, a protein kinase that performs diverse functions related to cell survival, thus preventing viruses from gaining ingredients such as nucleic acids to create a new virus, Soong said.
“Silmitasertib offers two advantages. First, its safety has been proven during our previous tests on about 300 people for cancer treatment. And second, we have about 120kg of Simitasertib in storage in the US, which would be convenient in terms of delivery to the NIH,” he said.
Given that Silmitasertib, unlike other potential new drugs under testing for COVID-19, such as remdesivir, does not directly attack the coronavirus or reduce lung damage, it is more likely to be used as a adjuvant drug, Soong said.
However, whether it would be effective and how it would be used with other medication would be determined by the NIH, Soong said.
Silmitasertib marks the only CK2 inhibitor present in clinical trials, he said.
The drug is undergoing a few human tests, including a Phase II trial for bile duct cancer in Taiwan, the US and South Korea, a Phase II clinical trial for medulloblastoma, sponsored by the National Institute of Health-Cancer Therapy Evaluation Program and the Pediatric Brain Tumor Consortium, and a Phase I study for advanced basal cell carcinoma, it said.
BYPASSING CHINA TARIFFS: In the first five months of this year, Foxconn sent US$4.4bn of iPhones to the US from India, compared with US$3.7bn in the whole of last year Nearly all the iPhones exported by Foxconn Technology Group (富士康科技集團) from India went to the US between March and last month, customs data showed, far above last year’s average of 50 percent and a clear sign of Apple Inc’s efforts to bypass high US tariffs imposed on China. The numbers, being reported by Reuters for the first time, show that Apple has realigned its India exports to almost exclusively serve the US market, when previously the devices were more widely distributed to nations including the Netherlands and the Czech Republic. During March to last month, Foxconn, known as Hon Hai Precision Industry
Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) and the University of Tokyo (UTokyo) yesterday announced the launch of the TSMC-UTokyo Lab to promote advanced semiconductor research, education and talent development. The lab is TSMC’s first laboratory collaboration with a university outside Taiwan, the company said in a statement. The lab would leverage “the extensive knowledge, experience, and creativity” of both institutions, the company said. It is located in the Asano Section of UTokyo’s Hongo, Tokyo, campus and would be managed by UTokyo faculty, guided by directors from UTokyo and TSMC, the company said. TSMC began working with UTokyo in 2019, resulting in 21 research projects,
Ashton Hall’s morning routine involves dunking his head in iced Saratoga Spring Water. For the company that sells the bottled water — Hall’s brand of choice for drinking, brushing his teeth and submerging himself — that is fantastic news. “We’re so thankful to this incredible fitness influencer called Ashton Hall,” Saratoga owner Primo Brands Corp’s CEO Robbert Rietbroek said on an earnings call after Hall’s morning routine video went viral. “He really helped put our brand on the map.” Primo Brands, which was not affiliated with Hall when he made his video, is among the increasing number of companies benefiting from influencer
Quanta Computer Inc (廣達) chairman Barry Lam (林百里) yesterday expressed a downbeat view about the prospects of humanoid robots, given high manufacturing costs and a lack of target customers. Despite rising demand and high expectations for humanoid robots, high research-and-development costs and uncertain profitability remain major concerns, Lam told reporters following the company’s annual shareholders’ meeting in Taoyuan. “Since it seems a bit unworthy to use such high-cost robots to do household chores, I believe robots designed for specific purposes would be more valuable and present a better business opportunity,” Lam said Instead of investing in humanoid robots, Quanta has opted to invest
RSS